vs
BIODESIX INC（BDSX）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
REGIS CORP的季度营收约是BIODESIX INC的2.0倍（$57.1M vs $28.8M），REGIS CORP净利率更高（0.8% vs -13.8%，领先14.6%），BIODESIX INC同比增速更快（40.8% vs 22.3%），REGIS CORP自由现金流更多（$891.0K vs $692.0K），过去两年BIODESIX INC的营收复合增速更高（39.3% vs 7.8%）
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
BDSX vs RGS — 直观对比
营收规模更大
RGS
是对方的2.0倍
$28.8M
营收增速更快
BDSX
高出18.5%
22.3%
净利率更高
RGS
高出14.6%
-13.8%
自由现金流更多
RGS
多$199.0K
$692.0K
两年增速更快
BDSX
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $28.8M | $57.1M |
| 净利润 | $-4.0M | $456.0K |
| 毛利率 | — | — |
| 营业利润率 | -6.8% | 10.8% |
| 净利率 | -13.8% | 0.8% |
| 营收同比 | 40.8% | 22.3% |
| 净利润同比 | 51.8% | -94.0% |
| 每股收益（稀释后） | $-3.35 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDSXRGS
| Q4 25 | $28.8M | $57.1M | ||
| Q3 25 | $21.8M | $59.0M | ||
| Q2 25 | $20.0M | $60.4M | ||
| Q1 25 | $18.0M | $57.0M | ||
| Q4 24 | $20.4M | $46.7M | ||
| Q3 24 | $18.2M | $46.1M | ||
| Q2 24 | $17.9M | $49.4M | ||
| Q1 24 | $14.8M | $49.2M |
净利润BDSXRGS
| Q4 25 | $-4.0M | $456.0K | ||
| Q3 25 | $-8.7M | $1.4M | ||
| Q2 25 | $-11.5M | $116.5M | ||
| Q1 25 | $-11.1M | $250.0K | ||
| Q4 24 | $-8.3M | $7.6M | ||
| Q3 24 | $-10.3M | $-853.0K | ||
| Q2 24 | $-10.8M | $91.2M | ||
| Q1 24 | $-13.6M | $-2.3M |
营业利润率BDSXRGS
| Q4 25 | -6.8% | 10.8% | ||
| Q3 25 | -32.4% | 10.0% | ||
| Q2 25 | -48.6% | 12.1% | ||
| Q1 25 | -50.9% | 8.8% | ||
| Q4 24 | -32.5% | 11.8% | ||
| Q3 24 | -47.3% | 4.6% | ||
| Q2 24 | -46.0% | — | ||
| Q1 24 | -74.4% | 8.3% |
净利率BDSXRGS
| Q4 25 | -13.8% | 0.8% | ||
| Q3 25 | -40.0% | 2.3% | ||
| Q2 25 | -57.3% | 192.9% | ||
| Q1 25 | -61.8% | 0.4% | ||
| Q4 24 | -40.4% | 16.4% | ||
| Q3 24 | -56.5% | -1.9% | ||
| Q2 24 | -60.3% | 184.7% | ||
| Q1 24 | -91.9% | -4.7% |
每股收益（稀释后）BDSXRGS
| Q4 25 | $-3.35 | $0.16 | ||
| Q3 25 | $-1.16 | $0.49 | ||
| Q2 25 | $-0.08 | $43.67 | ||
| Q1 25 | $-0.08 | $0.08 | ||
| Q4 24 | $-5.02 | $2.71 | ||
| Q3 24 | $-1.40 | $-0.36 | ||
| Q2 24 | $-0.08 | $38.40 | ||
| Q1 24 | $-0.14 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $18.4M |
| 总债务越低越好 | $50.0M | $113.3M |
| 股东权益账面价值 | $-2.5M | $188.7M |
| 总资产 | $87.5M | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资BDSXRGS
| Q4 25 | $19.0M | $18.4M | ||
| Q3 25 | $16.6M | $16.6M | ||
| Q2 25 | $20.7M | $17.0M | ||
| Q1 25 | $17.6M | $13.3M | ||
| Q4 24 | $26.2M | $10.2M | ||
| Q3 24 | $31.4M | $6.3M | ||
| Q2 24 | $42.2M | $10.1M | ||
| Q1 24 | $11.5M | $5.9M |
总债务BDSXRGS
| Q4 25 | $50.0M | $113.3M | ||
| Q3 25 | $50.0M | $111.3M | ||
| Q2 25 | $50.0M | $110.8M | ||
| Q1 25 | $40.0M | $112.0M | ||
| Q4 24 | $40.0M | $111.5M | ||
| Q3 24 | $40.0M | $95.2M | ||
| Q2 24 | $40.1M | $99.5M | ||
| Q1 24 | $40.1M | $179.7M |
股东权益BDSXRGS
| Q4 25 | $-2.5M | $188.7M | ||
| Q3 25 | $-1.7M | $187.6M | ||
| Q2 25 | $1.1M | $185.6M | ||
| Q1 25 | $11.1M | $68.6M | ||
| Q4 24 | $20.9M | $66.7M | ||
| Q3 24 | $27.9M | $56.4M | ||
| Q2 24 | $36.3M | $56.8M | ||
| Q1 24 | $-5.5M | $-35.8M |
总资产BDSXRGS
| Q4 25 | $87.5M | $588.3M | ||
| Q3 25 | $88.7M | $592.1M | ||
| Q2 25 | $87.7M | $599.0M | ||
| Q1 25 | $86.2M | $511.2M | ||
| Q4 24 | $97.2M | $530.1M | ||
| Q3 24 | $102.7M | $508.9M | ||
| Q2 24 | $115.8M | $530.5M | ||
| Q1 24 | $87.2M | $543.7M |
负债/权益比BDSXRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | 43.95× | 0.60× | ||
| Q1 25 | 3.62× | 1.63× | ||
| Q4 24 | 1.92× | 1.67× | ||
| Q3 24 | 1.44× | 1.69× | ||
| Q2 24 | 1.10× | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $778.0K | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $692.0K | $891.0K |
| 自由现金流率自由现金流/营收 | 2.4% | 1.6% |
| 资本支出强度资本支出/营收 | 0.3% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | $-23.5M | $14.9M |
8季度趋势，按日历期对齐
经营现金流BDSXRGS
| Q4 25 | $778.0K | $1.7M | ||
| Q3 25 | $-8.9M | $2.3M | ||
| Q2 25 | $-6.6M | $6.8M | ||
| Q1 25 | $-8.6M | $6.2M | ||
| Q4 24 | $-4.1M | $2.1M | ||
| Q3 24 | $-10.7M | $-1.3M | ||
| Q2 24 | $-18.6M | $5.1M | ||
| Q1 24 | $-15.3M | $-277.0K |
自由现金流BDSXRGS
| Q4 25 | $692.0K | $891.0K | ||
| Q3 25 | $-8.9M | $1.9M | ||
| Q2 25 | $-6.6M | $6.2M | ||
| Q1 25 | $-8.7M | $5.9M | ||
| Q4 24 | $-4.9M | $1.7M | ||
| Q3 24 | $-10.9M | $-1.4M | ||
| Q2 24 | $-20.5M | $5.1M | ||
| Q1 24 | $-15.5M | $-326.0K |
自由现金流率BDSXRGS
| Q4 25 | 2.4% | 1.6% | ||
| Q3 25 | -41.0% | 3.2% | ||
| Q2 25 | -33.1% | 10.3% | ||
| Q1 25 | -48.3% | 10.3% | ||
| Q4 24 | -24.2% | 3.6% | ||
| Q3 24 | -60.1% | -3.0% | ||
| Q2 24 | -114.3% | 10.3% | ||
| Q1 24 | -104.9% | -0.7% |
资本支出强度BDSXRGS
| Q4 25 | 0.3% | 1.4% | ||
| Q3 25 | 0.2% | 0.7% | ||
| Q2 25 | 0.3% | 0.9% | ||
| Q1 25 | 0.4% | 0.6% | ||
| Q4 24 | 4.1% | 0.9% | ||
| Q3 24 | 1.3% | 0.0% | ||
| Q2 24 | 10.7% | 0.0% | ||
| Q1 24 | 1.6% | 0.1% |
现金转化率BDSXRGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
